Characteristics of breast cancer patients with central nervous system metastases: A single-center experience

Journal of the National Medical Association

Volumn 100, Issue 5, 2008, Pages 521-533

  Harputluoglu, Hakan ^a   Dizdar, Omer ^a   Aksoy, Sercan ^a   Kilickap, Saadettin ^a   Dede, Didem S ^a   Ozisik, Yavuz ^a   Guler, Nilufer ^a   Barista, Ibrahim ^a   Gullu, Ibrahim ^a   Hayran, Mutlu ^a   Selek, Ugur ^a   Cengiz, Mustafa ^a   Zorlu, Faruk ^a   Tekuzman, Gulten ^a   Altundag, Kadri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Brain; Breast cancer; Metastasis; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

EID: 44149105189     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0027-9684(15)31298-0     Document Type: Article

References (29)

1. E.S. Nussbaum H.R. Djalilian K.H. Cho Brain metastases. Histology, multiplicity, surgery, and survival Cancer 78 1996 1781 1788
2. Y. Tsukada A. Fouad J.W. Pickren Central nervous system metastasis from breast carcinoma. Autopsy study Cancer 52 1983 2349 2354
3. W. Boogerd V.W. Vos A.A. Hart Brain metastases in breast cancer; natural history, prognostic factors and outcome J Neurooncol 15 1993 165 174
4. N.U. Lin J.R. Bellon E.P. Winer CNS metastases in breast cancer J Clin Oncol 22 2004 3608 3617
5. L. Gaspar C. Scott M. Rotman Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials Int J Radiat Oncol Biol Phys 37 1997 745 751
6. A.J. Evans J.J. James E.J. Cornford Brain metastases from breast cancer: identification of a high-risk group Clin Oncol (R Coll Radiol) 16 2004 345 349
7. D.G. Hicks S.M. Short N.L. Prescott Breast cancers with brain metas-tases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR Am J Surg Pathol 30 2006 1097 1104
8. K.D. Miller T. Weathers L.G. Haney Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival Ann Oncol 14 2003 1072 1077
9. Y.L. Tham K. Sexton R. Kramer Primary breast cancer phenotypes associated with propensity for central nervous system metastases Cancer 107 2006 696 704
10. F.J. Lagerwaard P.C. Levendag P.J. Nowak Identification of prognostic factors in patients with brain metastases: a review of 1292 patients Int J Radiat Oncol Biol Phys 43 1999 795 803
11. K. Altundag M.L. Bondy N.Q. Mirza Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis Cancer 110 2007 2640 2647
12. B.C. Pestalozzi D. Zahrieh K.N. Price Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Ann Oncol 17 2006 935 944
13. N.U. Lin E.P. Winer Brain metastases: the HER2 paradigm Clin Cancer Res 13 2007 1648 1655
14. D.G. Kirsch C.J. Ledezma C.S. Mathews Survival after brain metasta-ses from breast cancer in the trastuzumab era J Clin Oncol 23 2005 2114 2116 author reply 2116–2117.
15. J.H. Suh B. Stea A. Nabid Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases J Clin Oncol 24 2006 106 114
16. M. Pegram D. Chan R. Dichmann Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer Breast Cancer Res Treat 100 2006 S28 (Abstract 301)
17. C.E. Geyer J. Forster D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743
18. M.T. Liu C.Y. Hsieh A.Y. Wang Prognostic factors affecting the outcome of brain metastases from breast cancer Support Care Cancer 14 2006 936 942
19. D. Palmieri A.F. Chambers B. Felding-Habermann The biology of metastasis to a sanctuary site Clin Cancer Res 13 2007 1656 1662
20. E.I. Chen J. Hewel J.S. Krueger Adaptation of energy metabolism in breast cancer brain metastases Cancer Res 67 2007 1472 1486
21. D.W. Andrews C.B. Scott P.W. Sperduto Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial Lancet 363 2004 1665 1672
22. R.K. Bindal R. Sawaya M.E. Leavens Surgical treatment of multiple brain metastases J Neurosurg 79 1993 210 216
23. M. van Vulpen H.B. Kal M.J. Taphoorn Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review) Oncol Rep 9 2002 683 688
24. A. Tosoni M. Ermani A.A. Brandes The pathogenesis and treatment of brain metastases: a comprehensive review Crit Rev Oncol Hematol 52 2004 199 215
25. A. Fabi A. Vidiri G. Ferretti Dramatic regression of multiple brain metastases from breast cancer with Capecitabine: another arrow at the bow? Cancer Invest 24 2006 466 468
26. E.A. Lien K. Wester P.E. Lonning Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients Br J Cancer 63 1991 641 645
27. M. Salvati L. Cervoni G. Innocenzi Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases Tumori 79 1993 359 362
28. H.J. Stemmler M. Schmitt A. Willems Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier Anti-cancer Drugs 18 2007 23 28
29. N. Lin L. Carey M. Liu Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer J Clin Oncol 24 2006 3s